AGIO Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 6.41%, SMA50 8.35%, SMA200 -12.05%). The stock’s 14-day RSI is 62.23 (firm momentum), while the ATR of 1.18 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -34.83% below its high and over 34.8% above its low. Average 10-day trading volume of 1.19 million shares is in line with the 3-month average of 1.16 million, indicating normal recent market interest.

Agios Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$9.60. This means the shares are trading below this model’s fair value.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) closed at $40.55 USD, losing -$0.68 (-1.65%) from the previous close of $41.23. The stock is currently mid-range between its 52-week high and low $22.24 and $46.00. With a market capitalization of about $2.41 billion, Agios Pharmaceuticals, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.54). Key stats such as the average daily volume over the past year has been around 1.16 million shares, volume is running light vs its 52-week average. Headquartered in Cambridge, MA, Agios Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Brian Goff, the company employs approximately 540 people and listed since July 24, 2013. Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields.

Agios Pharmaceuticals, Inc. has 59.47 million shares outstanding. The public float is 50.06 million shares, elevated short interest at 11.72% of float. This equals 6.90 million shares. The short ratio is 7.28 days. Institutional investors hold 109.94% of the float. Insiders own 1.11%. CELGENE CORP /DE/ holds 1.78 million shares, Goff Brian has 177.60 thousand shares and FOUSE JACQUALYN A has 149.22 thousand shares. Over the past six months, insider transactions show net selling. They sold 49.51 thousand shares across 15 transactions.

Agios Pharmaceuticals, Inc. generated EPS of -$7.12 over the past year. Five-year average earnings growth is -8.46%. Wall Street analysts project EPS growth of 21.54% annually over the next five years. The latest quarter delivered EPS of -$1.69. The next quarter is forecast at -$1.79. Next year's EPS is expected at -$1.48. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 17 Buy ratings, 8 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $65.00 to $25.00. The high target offers 60.3% upside. The low target suggests -38.35% downside. The mean target is $40.75. This offers 0.49% upside. Agios Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended April 29, 2026, missed forecasts by -6.63%. The prior quarter beat by -6.09%. Over the last six quarters, Apple has recorded several small beats. These include 2.96% in February 13, 2025.

Agios Pharmaceuticals, Inc. trades at a P/E ratio of -5.57, slightly below the S&P 500 average, with a price-to-sales ratio of 36.37 and a price-to-book ratio of 2.14 suggesting the stock is closer to book value. The P/FCF stands at -6.24, also below market averages.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares are flat -1.98% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Agios Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -5.57. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $49.36, suggesting 21.73% upside. Our AI forecast model points to short-term strength (16.15% over two weeks), a medium-term rise (2.05% over three months), and a longer-term loss (-1.38% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Agios Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 16.15%, with price expected at $47.10 by July 27, 2026, within a range of $45.64 to $48.70 3-Month Outlook: Projected rise of 2.05%, reaching $41.38 by October 09, 2026, with a range of $40.16 to $42.76. 1-Year Outlook: Projected loss of -1.38%, with price at $39.99 by July 13, 2027, within a range of $37.01 to $42.74.